- Home
- SLGB vs ACRV Comparison
SLGB vs ACRV Comparison
Compare SLGB & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | ACRV |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3M | 52.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SLGB | ACRV |
|---|---|---|
| Price | $0.90 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 75.3K | ★ 786.4K |
| Earning Date | 05-16-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $691.78 |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $1.05 |
| 52 Week High | $6.02 | $3.56 |
Technical Indicators
Market Signals| Indicator | SLGB | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 33.94 | 33.67 |
| Support Level | N/A | $1.22 |
| Resistance Level | $1.48 | $1.44 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 13.47 | 4.55 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.